Progression-Free Survival (PFS)
(Redirected from progression-free survival (PFS))
Jump to navigation
Jump to search
A Progression-Free Survival (PFS) is an healthcare measure based on the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.
- …
- Counter-Example(s):
- See: Oncology, Clinical Research Endpoint.
References
2022
- (Wikipedia, 2022) ⇒ https://en.wikipedia.org/wiki/Progression-free_survival Retrieved:2022-2-10.
- Progression-free survival (PFS) is "the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse". In oncology, PFS usually refers to situations in which a tumor is present, as demonstrated by laboratory testing, radiologic testing, or clinically. Similarly, "disease-free survival" is the length of time after patients have received treatment and have no detectable disease. Time to progression (TTP) does not count patients who die from other causes but is otherwise a close equivalent to PFS (unless there are many such events). The FDA gives separate definitions and prefers PFS.
2021
- (Wikipedia, 2021) ⇒ https://en.wikipedia.org/wiki/Clinical_endpoint#Scope Retrieved:2021-11-15.
- … A clinical trial will usually define or specify a primary endpoint as a measure that will be considered success of the therapy being trialled (e.g. in justifying a marketing approval). The primary endpoint might be a statistically significant improvement in overall survival (OS). A trial might also define one or more secondary endpoints such as progression-free-survival (PFS) that will be measured and are expected to be met. A trial might also define exploratory endpoints that are less likely to be met. ...
2021
- https://www.frontiersin.org/articles/10.3389/fonc.2021.672916/full
- QUOTE: ... In clinical trials that assess novel therapeutic agents in patients with non-small-cell lung cancer (NSCLC), overall survival (OS) is considered the gold-standard endpoint for establishing clinical benefit (1–3). ‘Early’ endpoints, such as progression-free survival (PFS) and objective response rate (ORR), ...
... Furthermore, high-quality real-world evidence (RWE) could be leveraged to enable drug approvals in oncology, linking it to the value proposition of drugs. Regulatory bodies, such as the US Food and Drug Administration, have recently shown a willingness to expedite access to new cancer medicines by using RWE ...
- QUOTE: ... In clinical trials that assess novel therapeutic agents in patients with non-small-cell lung cancer (NSCLC), overall survival (OS) is considered the gold-standard endpoint for establishing clinical benefit (1–3). ‘Early’ endpoints, such as progression-free survival (PFS) and objective response rate (ORR), ...
2020
- https://metastatictrialtalk.org/inside-clinical-trials/progression-free-survival-vs-overall-survival/
- QUOTE: ... In some trials, researchers set out to look at progression-free survival (PFS), a measure of how long someone is on a treatment before their cancer starts to grow. They can also look at overall survival (OS), or how long someone lives after starting on a treatment. ...